Contents required for farnesol ointment.

Leishmaniasis is a zoonotic disease transmitted by an obligate intra-macrophage protozoan of the genus Leishmania through the infective bite of a vector sandfly. This study investigated the therapeutic efficacy of farnesol, a sesquiterpene compound, for the treatment of cutaneous leishmaniasis (CL) using in vivo BALB/c mouse model. In this study, farnesol’s efficacy was compared with the standard drug, paromomycin. It was observed that farnesol significantly reduced lesion sizes and footpad thickness compared to the control group (paromomycin). Lymph node size was also significantly reduced in farnesol-treated mice, indicating its ability to control infection spread. Combination therapy with farnesol and Paromomycin did not demonstrate synergistic effects. These results highlight the potential of farnesol as an alternative therapeutic agent for CL. Further investigations are required to elucidate its mechanism of action and assess potential off-target effects. Optimization of oral delivery methods should be explored to enhance bioavailability. Overall, our findings support farnesol’s efficacy in CL treatment, offering promising prospects for improved disease management.

利什曼病是一类由利什曼原虫属（Leishmania）专性胞内寄生原生动物通过媒介昆虫白蛉的感染性叮咬所传播的人畜共患病。本研究采用BALB/c小鼠体内模型，探究了倍半萜类化合物法尼醇（farnesol）治疗皮肤利什曼病（cutaneous leishmaniasis，CL）的疗效，并将其与标准治疗药物巴龙霉素（paromomycin）进行对照比较。实验结果表明，与对照组（巴龙霉素给药组）相比，法尼醇可显著缩小皮损面积与足垫厚度；法尼醇给药小鼠的淋巴结体积亦显著降低，提示其可抑制感染扩散。法尼醇与巴龙霉素的联合治疗未表现出协同效应。本研究结果凸显了法尼醇作为皮肤利什曼病替代治疗制剂的潜力。后续仍需进一步阐明其作用机制，并评估潜在的脱靶效应；同时应探索口服给药方式的优化策略以提升其生物利用度。总体而言，本研究结果证实了法尼醇在皮肤利什曼病治疗中的有效性，为该疾病的诊疗管理提供了极具前景的新方向。